Find drug development pipeline and deal Updates information

Lead Product(s): SACT-1

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Alliance Global Partners

Deal Size: $10.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 26, 2020

Details:

Net proceeds from the offering will fund the continued research and development of its leading therapeutic candidates (including SACT-1 and ALS-4) into their respective clinical phases.